Classification: RAF/MEK complex inhibitor. Docks on RAF/MEK dimer interface and traps RAF/MEK complex in inactive state. Side effects: rash, elevated CPK, and diarrhea. Phase I is recruiting for solid tumors and multiple myeloma (NCT02407509). The gene discussed is RAF1; the disease is plasma cell myeloma.